For serum protein components, a recent pilot study of 298 patients with early RA (the Swedish Pharmacotherapy (SWEFOT) clinical trial) identified that low baseline levels of C-reactive protein (CRP) and leptin, and high baseline levels of tumor necrosis factor receptor I (TNF-RI) and vascular cell adhesion molecule 1 (VCAM-1), potentially predicted the response to methotrexate, that is, disease activity, based on the Disease Activity Score in the 28-joint erythrocyte sedimentation rate (DAS28-ESR) < 3.2, at a 3-month follow-up examination [3]. This evidence concerns the gene CRP and rheumatoid arthritis.